Acquisition of JB Chemicals by Tau Investment approved by CCI

Published On 2020-08-27 08:00 GMT   |   Update On 2021-11-22 11:37 GMT
Advertisement

Delhi : The Competition Commission of India (CCI) has approved the proposal of Tau Investment to acquire shares in J B Chemicals.

The proposed combination envisaged the acquisition of up to 64.90% of the share capital of J B Chemicals & Pharmaceuticals Limited by Tau Investment Holdings Pte. Ltd. (Tau Investment).

Tau Investment is a company incorporated in Singapore. It is an indirect wholly-owned subsidiary of KKR Asian Fund III L.P. It is an affiliate of funds, vehicles, and/or entities managed and/or advised by Kohlberg Kravis Roberts & Co. L.P., which is an indirect subsidiary of KKR & Co. Inc.

J B Chemicals & Pharmaceuticals Limited is an Indian pharmaceutical company, headquartered in Mumbai, Maharashtra. It is listed on BSE Limited and the National Stock Exchange of India Limited.

The detailed order of the CCI will follow.

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News